<i>In vitro</i> activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant <i>Acinetobacter baumannii</i> collected in U.S. hospitals
Alina Iovleva, Christi L. McElheny, Erin L. Fowler, Eric Cober, Erica Herc, César A. Arias, Carol Hill, Keri Baum, Vance G. Fowler, Henry F. Chambers, Kerryl E. Greenwood‐Quaintance, Robin Patel, David van Duin, Robert A. Bonomo, Yohei Doi
Abstract
ABSTRACT The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC 50 /MIC 90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.